Figures computed from official regulatory filings — .
Analysttarget 11 USD (+182%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 53.08% · institutions 15.66% · short 12.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GALECTIN THERAPEUTICS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
150 buys202 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Uihlein Richard Etrack record | Exercise | $95.5M | Unusual size | SEC |
| Uihlein Richard Etrack record | ExerciseD (derivative) | Value needs reviewn/a (Value under review) | SEC |
| Uihlein Richard Etrack record | ExerciseD (derivative) | Value needs reviewn/a (Value under review) | SEC |
| Uihlein Richard Etrack record | Exercise | $10.3M | Unusual size | SEC |
| Jamil Khurram | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jamil Khurram | Exercise | $49.4K | SEC |
| Jamil Khurram | Sell | $83.3K | SEC |
| Jamil Khurram | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shlevin Harold H. | Sell | $38.7K | SEC |
| Jamil Khurram | Sell | $12.7K | SEC |
| Jamil Khurram | Sell | $10.2K | SEC |
| Shlevin Harold H. | Sell | $112.2K | SEC |
| Shlevin Harold H. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jamil Khurram | Exercise | $6.3K | SEC |
| Jamil Khurram | Sell | $239.2K | Unusual size | SEC |
| Jamil Khurram | Exercise | $4.5K | SEC |
| Shlevin Harold H. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jamil Khurram | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shlevin Harold H. | Exercise | $9.5K | SEC |
| Jamil Khurram | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shlevin Harold H. | Exercise | $27.4K | SEC |
| Jamil Khurram | Exercise | $118.7K | Unusual size | SEC |
| Jamil Khurram | Sell | $23.7K | SEC |
| Jamil Khurram | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jamil Khurram | Exercise | $9.3K | SEC |